11/13/20

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

10/29/20

CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

10/29/20

Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

10/26/20

Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable

09/22/20

Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

09/17/20

Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

08/27/20

Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer

08/14/20

Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update

07/07/20

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

06/09/20

Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

05/14/20

Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update

05/13/20

Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

04/27/20

Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting

04/07/20

Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020

03/31/20

Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs

03/09/20

Vaccinex Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

02/06/20

Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium